Tag: preclinical assets market outlook

Discover trends, market shifts, and competitive outlooks for the preclinical assets industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Preclinical Assets Market In 2029?

The market size for preclinical assets has witnessed robust growth over the recent years, expanding from $5.87 billion in 2024 to an expected $6.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. Factors such as the need for drug development, progress in biotechnology, regulatory mandates, increased funding for research, and partnership in research efforts have contributed to the growth experienced in the historical period.

The market size for preclinical assets is anticipated to exhibit a robust expansion in the coming years. By 2029, it’s predicted to surge to a value of $9.3 billion, with a compound annual growth rate (CAGR) of 9.8%. The expected growth during the forecast span can be credited to factors such as precision medication and personalized treatment methods, AI and machine learning implementation, expansion of biobanking, focus on rare illnesses, as well as government efforts and financial backing. During the forecast period, major emerging trends include the advent of advanced imaging techniques, development of 3D organoid models, integration of multi-omics methods, enhanced predictive models, as well as increased automation and high-throughput screening.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What External and Internal Drivers Are Contributing to the Growth of thePreclinical Assets Market?

The surge in drug discovery is anticipated to fuel the expansion of the preclinical asset market in the future. Drug discovery involves the identification of chemical substances that can serve as medicinal agents, leading to the birth of potential new medications. Preclinical assets are integral to this process, providing crucial data and evidence to assist in the selection of molecules for clinical development. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based group representing the pharmaceutical sector, highlighted significant growth in the European pharmaceutical industry with production rising from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the escalating rate of drug discovery is accelerating the growth of the preclinical assets market.

What Segment Types Define the Preclinical Assets Market Structure?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Preclinical Assets Market?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Preclinical Assets Market?

The emergence of product innovations is a notable trend in the preclinical assets sector. Major players in this market are prioritizing the development of novel products and solutions to solidify their market standing and gain a competitive edge. For example, in April 2022, Charles River Laboratories International, an American pharmaceutical firm specialized in various preclinical and clinical laboratories, and Valo Health Inc., a tech firm from the US creating innovative drug discovery, introduced an AI-powered drug solution called Logica. This solution converts clients’ biological learnings into optimized preclinical assets. It takes advantage of Charles River’s advanced preclinical understanding and Valo’s Opal Computational Platform powered by AI to offer clients a revamped method of digging up new drugs. This integrated service seamlessly transitions clients’ targets to candidate nomination. Through collaborating with Valo, Charles River amalgamates its lab expertise with molecular design technology, thereby causing a profound transformation in the industry. It presents clients with highly competent leads and candidates, aligning client expenditure with value generation.

View the full report here:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

What Is the Definition of the Preclinical Assets Market?

A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the preclinical assets industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Preclinical Assets Market In 2029?

The market size for preclinical assets has witnessed robust growth over the recent years, expanding from $5.87 billion in 2024 to an expected $6.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. Factors such as the need for drug development, progress in biotechnology, regulatory mandates, increased funding for research, and partnership in research efforts have contributed to the growth experienced in the historical period.

The market size for preclinical assets is anticipated to exhibit a robust expansion in the coming years. By 2029, it’s predicted to surge to a value of $9.3 billion, with a compound annual growth rate (CAGR) of 9.8%. The expected growth during the forecast span can be credited to factors such as precision medication and personalized treatment methods, AI and machine learning implementation, expansion of biobanking, focus on rare illnesses, as well as government efforts and financial backing. During the forecast period, major emerging trends include the advent of advanced imaging techniques, development of 3D organoid models, integration of multi-omics methods, enhanced predictive models, as well as increased automation and high-throughput screening.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What External and Internal Drivers Are Contributing to the Growth of thePreclinical Assets Market?

The surge in drug discovery is anticipated to fuel the expansion of the preclinical asset market in the future. Drug discovery involves the identification of chemical substances that can serve as medicinal agents, leading to the birth of potential new medications. Preclinical assets are integral to this process, providing crucial data and evidence to assist in the selection of molecules for clinical development. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based group representing the pharmaceutical sector, highlighted significant growth in the European pharmaceutical industry with production rising from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the escalating rate of drug discovery is accelerating the growth of the preclinical assets market.

What Segment Types Define the Preclinical Assets Market Structure?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Preclinical Assets Market?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Preclinical Assets Market?

The emergence of product innovations is a notable trend in the preclinical assets sector. Major players in this market are prioritizing the development of novel products and solutions to solidify their market standing and gain a competitive edge. For example, in April 2022, Charles River Laboratories International, an American pharmaceutical firm specialized in various preclinical and clinical laboratories, and Valo Health Inc., a tech firm from the US creating innovative drug discovery, introduced an AI-powered drug solution called Logica. This solution converts clients’ biological learnings into optimized preclinical assets. It takes advantage of Charles River’s advanced preclinical understanding and Valo’s Opal Computational Platform powered by AI to offer clients a revamped method of digging up new drugs. This integrated service seamlessly transitions clients’ targets to candidate nomination. Through collaborating with Valo, Charles River amalgamates its lab expertise with molecular design technology, thereby causing a profound transformation in the industry. It presents clients with highly competent leads and candidates, aligning client expenditure with value generation.

View the full report here:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

What Is the Definition of the Preclinical Assets Market?

A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of thePreclinical Assets Market?

The upward trend in drug discovery is predicted to boost the expansion of the preclinical asset market in the future. Drug discovery involves the identification of chemical substances with potential medicinal properties, marking the birth of new possible medications. Preclinical assets serve a crucial function in this procedure, contributing crucial data and validation to assist in the selection of molecules for clinical development. For instance, as reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA) – a Belgium-based entity advocating for the pharmaceutical sector, there was a significant increase in the European pharmaceutical industry’s production in June 2023, escalating from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the growth of the preclinical assets market is being propelled by the escalating drug discovery.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

How Will the Growth Rate of thePreclinical Assets Market Impact Industry Trends by 2034?

In recent times, the size of the preclinical assets market has witnessed robust growth. It is projected to intensify from $5.87 billion in 2024 to $6.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. The surge during the historical period may be credited to the demands for drug development, advancements in biotechnology, regulatory prerequisites, the expansion of research funding, and collaborative research endeavors.

The market for preclinical assets is anticipated to experience a robust growth in the coming years. With a compound annual growth rate (CAGR) of 9.8%, it is predicted to surge to $9.3 billion by 2029. Factors driving this growth during the forecast period include the rising prominence of precision medicine and personalized therapies, the integration of artificial intelligence and machine learning, expansion of biobanking, heightened focus on rare diseases, and governmental initiatives and funding. Moreover, emerging trends within the forecast period such as advanced imaging techniques, 3D organoid models, integration of multi-omics, improved predictive models, automation, and high throughput screening will further stimulate the market growth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

Which Upcoming Market Trends and Innovations Are Set to Influence the Preclinical Assets Market’s Path Forward?

The growing trend of product innovations is making substantial headway in the preclinical assets market, as primary companies in this sector focus on the introduction of new products and solutions for solidifying their market standing and for securing a competitive edge. For instance, in April 2022, Charles River Laboratories International, a pharmaceutical company based in the US with numerous preclinical and clinical laboratories, alongside Valo Health Inc., a US-based tech firm aiming to revolutionize drug discovery, together initiated Logica, an AI-powered drug solution. This solution effectively transforms clients’ biological findings into optimized preclinical assets. Logica utilizes the superior preclinical knowledge of Charles River and the AI-enabled Opal Computational Platform of Valo to offer clients a unique drug discovery method through a single, integrated package that seamlessly turns targets into candidate nominations. By associating with Valo, Charles River merges its lab expertise with molecular design technology, thereby wreaking a significant transformation in the industry. This collaboration ensures the delivery of highly suitable leads and candidates to clients while tying client expenses to value generation.

Who Are the Dominant Market Players Pushing the Boundaries of thePreclinical Assets Market?

Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

#thebusinessresearchcompany #marketresearch #marketintelligence

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

What Regions Are Dominating the Preclinical Assets Market Growth?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Preclinical Assets Maret 2025, By The Business Research Company:

Asset-Backed Securities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/asset-backed-securities-global-market-report

Preclinical Imaging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preclinical-imaging-global-market-report

Defense IT Spending Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/defense-it-spending-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the preclinical assets market grown over the years?

In recent years, there has been robust growth in the market size for preclinical assets. This market is projected to expand from $5.87 billion in 2024 to $6.4 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 9.1%. This historical growth trend can be linked to several factors such as demands for drug development, advancements in biotechnology, regulatory obligations, the expansion of research funding, and joint research initiatives.

What Is the forecasted market size and growth rate for the preclinical assets market?

The projected growth of the preclinical assets market is robust, with estimates suggesting it will reach $9.3 billion by 2029, expanding at a compound annual growth rate (CAGR) of 9.8%. Various factors are driving this growth within the forecast period, such as advancements in precision medicine and tailored therapies, integration of artificial intelligence and machine learning, expansion of biobanking, a focus on rare diseases, as well as government initiatives and funding. Within this growth period, several trends are expected to emerge including advanced imaging techniques, 3D organoid models, integration of multi-omics, improved predictive models, along with automation and high throughput screening.

Get your preclinical assets market report here!

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

What are the major factors driving growth in the preclinical assets market?

The escalation in drug discovery is projected to drive the expansion of the preclinical asset market in the future. Drug discovery involves identifying chemical compounds that have potential to be used as therapeutic agents. This is the method by which new potential drugs are identified. Preclinical assets are critical to this process as they provide the necessary information and proof to assist in choosing molecules for clinical development. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based group representing the pharmaceutical industry, reported in June 2023 that the European pharmaceutical industry saw significant production growth, increasing from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the growth of the preclinical assets market is being fueled by the surge in drug discovery.

What key areas define the segmentation of the global preclinical assets Market?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What are the top market players propelling the growth of the preclinical assets industry?

Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

What are the key trends shaping the future of the preclinical assets market?

The trend towards product innovation is gaining traction in the preclinical assets sector. Key players in this market space are honing in on creating new products and solutions to solidify their market standing and secure a competitive edge. For example, in April 2022, Charles River Laboratories International, a US corporation specializing in preclinical and clinical laboratories, alongside Valo Health Inc., a technology company with a mission to revolutionize drug discovery, unveiled Logica, a drug solution powered by artificial intelligence (AI). Logica turns the biological insights of clients into refined preclinical assets, employing the superior preclinical acumen of Charles River and the AI-enabled Opal Computational Platform of Valo. This allows clients to transform their drug discovery processes through a comprehensive, integrated service that seamlessly converts targets into candidate nominations. In this collaboration with Valo, Charles River intertwines its lab expertise with molecular design technology, igniting a revolution in the industry to provide clients with highly-qualified leads and candidates, all while linking the client’s cost directly to value generation.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

What regions are dominating the preclinical assets market growth?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Asset-Backed Securities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/asset-backed-securities-global-market-report

Preclinical Imaging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preclinical-imaging-global-market-report

Defense IT Spending Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/defense-it-spending-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Preclinical Assets Market During the Forecast Period, and Why?

The preclinical assets market has expanded strongly in recent years. It is forecasted to increase from $5.87 billion in 2024 to $6.4 billion in 2025, at a CAGR of 9.1%. The historical expansion of this market has been supported by the growing need for drug development, progress in biotechnology, evolving regulatory requirements, rising research funding, and collaborative research initiatives.

The Preclinical Assets market is expected to witness strong growth, reaching $9.3 billion in 2029 at a CAGR of 9.8%. Growth drivers include the rise of precision medicine and personalized therapies, AI and machine learning applications, biobanking expansion, a growing focus on rare diseases, and government funding and initiatives. Notable trends in this market include advancements in imaging techniques, the use of 3D organoid models, multi-omics integration, enhanced predictive models, and automation with high-throughput screening.

What Key Drivers Are Accelerating the Growth of the preclinical assets Market During the Forecast Period?

The growing rate of drug discovery is expected to accelerate the growth of the preclinical assets market. Drug discovery identifies new chemical substances that can become medicines, and preclinical assets provide essential data to select candidates for clinical trials. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations noted a significant rise in the European pharmaceutical industry’s production, growing from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the rise in drug discovery is supporting the preclinical assets market.

Request Your Free Preclinical Assets Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

Which Companies Are Poised to Shape the Future of the Preclinical Assets Market?

Major companies operating in the preclinical assets market include:

• Laboratory Corporation of America_x000D_

• IQVIA Inc._x000D_

• ICON PLC_x000D_

• Eurofins Scientific SE_x000D_

• PPD Inc._x000D_

What Are the Latest Innovations and Trends Influencing the Preclinical Assets Market?

Product innovation is key in the preclinical assets market, where companies are introducing new solutions to strengthen their market position. For example, in April 2022, Charles River Laboratories International, a US-based pharmaceutical company, and Valo Health Inc., a US-based technology company, launched Logica, an AI-powered drug solution. Logica translates biological insights into optimized preclinical assets by integrating Charles River’s preclinical expertise with Valo’s AI-powered platform, revolutionizing drug discovery and providing clients with highly qualified leads.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

What Are the Major Categories and Their Growth Dynamics in the Preclinical Assets Market?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

What Regions Are Contributing Significantly to the Growth of the Preclinical Assets Market?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Scope and Reach of the Preclinical Assets Market Defined?

A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals.

Browse Through More Similar Reports By The Business Research Company:

Asset-Backed Securities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/asset-backed-securities-global-market-report

Preclinical Imaging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preclinical-imaging-global-market-report

Defense IT Spending Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/defense-it-spending-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: